IL2 and melanoma: About 20 percent of patients with melanoma will ultimately develop distant metastases; prognosis remains poor despite novel treatment modalities; single-agent or multiple-agent chemotherapy, biological therapy (interferon-alpha, interleukin-2), radiotherapy, and biochemotherapy have failed to demonstrate a consistent survival benefit in advanced systemic disease [5].